Welcome to our dedicated page for QuidelOrtho SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QuidelOrtho's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QuidelOrtho's regulatory disclosures and financial reporting.
QuidelOrtho Corp executive Bryan Michael Hanson, EVP Global Portfolio Management & Marketing, released 5,797 restricted stock units into an equal number of common shares on July 1, 2026. To satisfy tax obligations, 2,096 shares were withheld at $18.18 per share. After these transactions, he directly held 7,771 shares of common stock. Footnotes indicate an additional 5,797 RSUs are scheduled to vest on July 1, 2027 and 5,798 on July 1, 2028.
QuidelOrtho Corp director Kenneth J. Widder received several equity-based awards in the form of restricted stock units (RSUs). On June 25, 2026, he was granted 1,997 premium RSUs, 6,656 converted RSUs, and 15,532 equity grant RSUs, each representing one share of common stock. The RSUs were issued in lieu of certain cash retainer and board service fees under a deferred compensation program and vest on a scheduled basis, including full vesting for one grant on June 25, 2027 and four installments of 1,664 shares between June 25, 2026 and March 25, 2027.
Huennekens R Scott reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp director R. Scott Huennekens received a grant of restricted stock units as equity compensation. He was awarded 15,532 restricted stock units representing the right to receive an equal number of shares of QuidelOrtho common stock. These restricted stock units will vest on June 25, 2027, and following the grant he holds 15,532 such units directly.
QuidelOrtho Corp director John R. Chiminski reported awards of restricted stock units (RSUs) linked to common stock. On June 25, 2026, he acquired 1,109 premium RSUs, 5,547 converted RSUs, and 15,532 equity grant RSUs as compensation.
Each RSU represents one share of QuidelOrtho common stock and carries a grant price of $0.00 per unit. One set of RSUs will vest on June 25, 2027, while an additional 1,386 units vested on June 25, 2026 and 1,387 units are scheduled to vest on each of September 25, 2026, December 25, 2026 and March 25, 2027. The RSUs were received in lieu of cash fees under a deferred compensation program for non‑employee directors, with release of vested units following the director’s elected deferral schedule.
Wilkins Joseph D Jr. reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp director receives RSU award
QuidelOrtho Corp director Joseph D. Wilkins Jr. received a grant of 15,532 restricted stock units. Each unit represents the right to receive one share of QuidelOrtho common stock if vesting conditions are met.
The restricted stock units will vest on June 25, 2027. Following this grant, Wilkins holds 15,532 RSUs directly, giving him a future equity stake tied to the company’s share performance once the award vests.
QuidelOrtho Corp director Ann D. Rhoads reported three equity compensation awards in the form of restricted stock units (RSUs). On June 25, 2026, she was granted 369 RSUs labeled as premium units, 3,698 RSUs labeled as converted units, and 15,532 RSUs as an equity grant, each representing one share of common stock when delivered.
The RSUs carry a stated value of $0.00 per unit because they are compensation awards rather than market purchases. One RSU tranche will vest on June 25, 2027, and another tranche is scheduled to vest in stages: 924 shares vested on June 25, 2026, 924 shares will vest on September 25, 2026, 925 shares on December 25, 2026, and 925 shares on March 25, 2027.
The filing explains that these RSUs were received in lieu of cash payments for certain retainer and Board service-related fees under a deferred compensation program for non-employee directors, with release of vested units following the director’s elected deferral schedule.
QuidelOrtho Corp director Mary Lake Polan, Ph.D., reported grants of restricted stock units tied to her board service. On June 25, 2026, she received three awards of premium, converted, and equity grant RSUs covering 1,664, 5,547 and 15,532 units, each representing one share of common stock. Some units vest entirely on June 25, 2027, while 1,386 units vested on June 25, 2026 and additional 1,387-unit tranches will vest on September 25, 2026, December 25, 2026, and March 25, 2027. The RSUs were received in lieu of cash retainers and board-related fees under a deferred compensation program for non-employee directors, with release of vested shares following her elected deferral schedule.
QuidelOrtho Corp director Michael Edward L. received several equity-based compensation awards in the form of restricted stock units on June 25, 2026. These awards are structured as premium, converted, and equity grant restricted stock units, each representing the right to receive one share of QuidelOrtho common stock.
The grants were made at a price of $0.00 per unit as compensation rather than open-market purchases. Footnotes explain that one set of restricted stock units will vest on June 25, 2027, and another set vests in four installments of 878, 878, 878, and 879 units on June 25, 2026, September 25, 2026, December 25, 2026, and March 25, 2027, respectively.
The awards were received in lieu of cash payments for certain retainer and Board of Director service-related fees under a deferred compensation program for participating non-employee directors. Vested units will be released according to the director’s elected deferral schedule, emphasizing that these are compensation-related equity grants rather than discretionary stock trades.
QuidelOrtho Corp director Evelyn S. Dilsaver received a grant of 15,532 restricted stock units (RSUs) as equity compensation. Each RSU corresponds to one share of QuidelOrtho common stock and was awarded at no exercise price. All 15,532 RSUs will vest on June 25, 2027, and her reported direct holdings in this RSU award total 15,532 units after the transaction.
QuidelOrtho Corp director Kenneth F. Buechler received equity-based compensation in the form of restricted stock units (RSUs) on June 25, 2026. He was granted 3,661 premium RSUs, 12,204 converted RSUs, and 15,532 equity grant RSUs, each representing one share of common stock.
The RSUs were awarded in lieu of cash retainer and other Board service-related fees under a deferred compensation program for non-employee directors. One RSU equals one share of QuidelOrtho common stock, with vesting noted to occur on June 25, 2027 for certain awards, and additional tranches of 3,051 shares vesting on June 25, 2026, September 25, 2026, December 25, 2026, and March 25, 2027.